Reverse-Payment Settlements

Hatch-Waxman makes the generic the defendant

When a generic files an ANDA with a Paragraph IV certification (asserting the brand's patent is invalid or not infringed), that filing is itself an act of infringement, so the BRAND sues the generic. The brand is the plaintiff; the generic is the defendant.

Normally settlement money flows plaintiff → defendant... backwards here

In a typical settlement, the defendant pays the plaintiff. In a reverse-payment deal the PLAINTIFF (brand) pays the DEFENDANT (generic) — hence 'reverse.' That unusual direction is the red flag: why would a plaintiff pay the party it sued?

The brand buys time; the generic shares the monopoly profit

A brand's monopoly profit on a blockbuster drug can dwarf what a generic would earn competing. The brand can pay the generic more than the generic would make by entering, and still come out ahead by preserving its monopoly price — both parties profit, at consumers' and payers' expense.

The 180-day exclusivity bottleneck amplifies it

The first generic to file a Paragraph IV ANDA earns 180 days of generic exclusivity. Paying off that first filer can bottleneck ALL later generics, because the clock on the first-filer's exclusivity may not start, delaying the whole generic market.

Rejected 'scope of the patent' immunity

Lower courts had largely held that a settlement was immune from antitrust attack as long as it kept generic entry within the time period the patent could have blocked (the 'scope of the patent' test). The Supreme Court rejected that — a patent does not automatically immunize anticompetitive payments.

Rejected per se illegality too

The FTC wanted reverse payments treated as presumptively unlawful (a 'quick look'). The Court declined to go that far — reverse-payment settlements are not automatically illegal either.

Adopted the rule of reason

The Court held that reverse-payment settlements must be analyzed under the antitrust 'rule of reason,' weighing anticompetitive effects against justifications, case by case. A large, unexplained payment can be evidence of market power and an attempt to avoid competition.

A large reverse payment is a danger signal

The Court emphasized that a payment large enough to exceed the brand's saved litigation costs and the value of any collateral services from the generic suggests the brand is paying to avoid the RISK of losing its patent — i.e., paying to preserve a possibly-invalid monopoly.

What is a reverse-payment (pay-for-delay) settlement?

A reverse-payment settlement — commonly called 'pay-for-delay' — is a settlement of pharmaceutical patent litigation in which the brand-name drug manufacturer pays the generic drug company to abandon its patent challenge and delay bringing its cheaper generic to market. It is called a 'reverse' payment because the money flows in the opposite direction from a normal settlement: ordinarily a defendant pays a plaintiff to settle, but here the PLAINTIFF (the brand that sued for infringement) pays the DEFENDANT (the generic it sued). The arrangement arises out of the Hatch-Waxman framework: a generic seeking to market before a brand's patents expire files an Abbreviated New Drug Application (ANDA) with a 'Paragraph IV' certification that the brand's patent is invalid or not infringed; that filing is an act of infringement, so the brand sues; the parties then sometimes settle on terms where the brand pays the generic and the generic agrees to stay off the market until an agreed date. Why both sides like it: the brand's monopoly profits on a blockbuster drug are typically far larger than the profits a generic would earn by competing, so the brand can pay the generic handsomely to delay entry and still preserve most of its monopoly pricing — the parties effectively split the monopoly profit that competition would have eliminated. The losers are consumers, insurers, and government health programs, who keep paying brand prices longer. Because the deals can preserve a monopoly that might not survive if the patent litigation ran its course (the patent might be invalid), they drew sustained antitrust scrutiny from the Federal Trade Commission, culminating in the Supreme Court's decision in FTC v. Actavis (2013).

What did FTC v. Actavis decide?

FTC v. Actavis, Inc., 570 U.S. 136 (2013), is the Supreme Court decision establishing how reverse-payment settlements are analyzed under antitrust law. The Court rejected both extremes and chose a middle path. (1) It rejected the 'scope of the patent' test that most lower courts had used, under which a settlement was immune from antitrust challenge so long as it kept the generic out only within the time the patent (if valid) could lawfully have excluded competition. The Court held that a patent does not automatically authorize anticompetitive payments — a patent's existence does not immunize a settlement from antitrust review, because the patent might be invalid or not infringed, and the public has an interest in testing weak patents rather than letting parties pay to preserve them. (2) It also rejected the FTC's request to treat reverse payments as presumptively unlawful ('quick look'); the deals are not automatically illegal. (3) Instead, the Court held that reverse-payment settlements must be evaluated under the antitrust 'rule of reason,' examining their actual competitive effects and any legitimate justifications. The Court reasoned that a large, otherwise-unexplained reverse payment is itself evidence that the brand has market power and is paying to avoid the risk of competition — essentially buying off a challenge to a patent it fears is invalid. The Court identified factors relevant to the analysis, including the size of the payment relative to the brand's anticipated future litigation costs and the value of any other services the generic provides, and whether the payment is justified by anything other than avoiding competition. Actavis did not decide whether any particular settlement was unlawful — it sent the legal standard back to be applied case by case, and a large body of post-Actavis litigation has since wrestled with how to apply the rule of reason, including to non-cash forms of value.

Why does the payment flow 'backwards' from plaintiff to defendant?

The reverse direction is a direct product of how Hatch-Waxman structures generic drug challenges, and it is the feature that makes these settlements suspicious. In ordinary litigation, a defendant accused of wrongdoing pays the plaintiff to settle — the money compensates the plaintiff for the alleged harm. In pharmaceutical Paragraph IV litigation, the roles are statutorily inverted: (1) The generic company files an ANDA with a Paragraph IV certification challenging the brand's patent (claiming it is invalid or not infringed). (2) Under 35 U.S.C. § 271(e)(2), filing that certification is itself defined as an act of patent infringement — a legal fiction that creates a justiciable case before the generic has actually sold anything. (3) So the BRAND (patent holder) becomes the plaintiff suing the generic, and the GENERIC becomes the defendant. When such a case settles with the brand PAYING the generic, the payment runs from plaintiff to defendant — backwards from the normal pattern. Economists and courts treat that backward flow as a signal because it is hard to explain on ordinary settlement logic: a plaintiff who believes in its case does not normally pay the defendant. The most coherent explanation is often that the brand is paying the generic not to compete — sharing some of the monopoly profit it preserves by keeping the generic off the market — which is precisely the competition-suppressing effect antitrust law scrutinizes. Hence the Supreme Court's focus in Actavis on a 'large and unjustified' reverse payment as evidence that the settlement is about avoiding competition rather than genuinely resolving a patent dispute.

Are all reverse-payment settlements illegal after Actavis?

No. Actavis did NOT make reverse-payment settlements per se illegal — it subjected them to rule-of-reason analysis, meaning each settlement is evaluated on its specific facts for actual anticompetitive effect weighed against legitimate justifications. Settlements that are lawful or defensible include: (1) Settlements with no payment, or only a payment that reflects a genuine, fair-value commercial transaction — for example, the brand paying the generic a reasonable amount for a real licensing or supply arrangement, or saved litigation costs, rather than to buy delay. (2) Early-entry settlements, where the generic agrees to enter the market BEFORE the patent expires (a pro-competitive outcome — the generic gets to market sooner than if the brand won the suit). (3) Settlements where the payment is small relative to the brand's avoided litigation costs and any services provided, so it does not look like a payment to avoid competition. What draws scrutiny and potential liability: a LARGE reverse payment that is not explained by litigation-cost savings or the fair value of other services — the kind of payment that suggests the brand is paying to preserve a monopoly it fears the patent cannot lawfully support. Post-Actavis developments practitioners track: (1) Courts have grappled with whether NON-CASH consideration — such as a 'no-authorized-generic' commitment (the brand agreeing not to launch its own competing generic during the first filer's exclusivity), favorable side deals, or inflated payments for unrelated products — counts as a reverse payment subject to scrutiny; many courts have said it can. (2) How to measure the payment's size and justification. (3) State enforcement and private antitrust suits by purchasers, alongside continued FTC enforcement. The practical takeaway for the industry: settlements remain available and common, but large unexplained payments to delay entry carry real antitrust risk, and deal structures are now drafted with Actavis in mind.

How do reverse-payment settlements relate to the 180-day generic exclusivity?

The 180-day generic exclusivity is a Hatch-Waxman incentive that, perversely, can amplify the anticompetitive effect of a pay-for-delay deal — which is part of why these settlements drew such concern. The mechanics: the FIRST generic company to file an ANDA with a Paragraph IV certification against a brand's patent is rewarded with 180 days of marketing exclusivity as the only generic — during that period the FDA will not approve later-filing generics. This is meant to reward the company that takes on the risk and cost of challenging the patent and opening the market to generic competition. The problem when combined with reverse payments: if the brand pays off the FIRST filer to delay its entry, the first filer's 180-day exclusivity may not be triggered or may sit unused, creating a bottleneck that blocks ALL subsequent generics from entering — because they cannot get final approval until the first filer's exclusivity is resolved. So a single pay-for-delay deal with the first filer can postpone the entire generic market, not just that one generic, multiplying the consumer harm. Congress and the FDA have addressed aspects of this over time — including provisions on forfeiture of the 180-day exclusivity in certain circumstances (e.g., failure to market within defined periods) designed to prevent a parked exclusivity from indefinitely blocking other generics, and a requirement (under the Medicare Modernization Act) that brand-generic patent settlements be filed with the FTC and DOJ so enforcers can review them. The interaction of the 180-day exclusivity, the bottleneck risk, and reverse payments remains a central theme in pharmaceutical antitrust, and 'no-authorized-generic' promises (where the brand agrees not to launch its own generic that would compete with and devalue the first filer's exclusivity) are a frequently litigated form of non-cash reverse payment.